A5027635834- Angiogenesis and VEGF in Cancer
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Bariatric Surgery and Outcomes
- Body Contouring and Surgery
- Breast Lesions and Carcinomas
- Diet and metabolism studies
- HER2/EGFR in Cancer Research
Shahid Beheshti University of Medical Sciences
2014-2024
Tehran University of Medical Sciences
2016
Background . Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule still remained undetermined. Objectives The feasibility of dose-dense epirubicin combination with cyclophosphamide (EC) followed by weekly paclitaxel as was investigated. Methods All were treated (100 mg/m 2 ) and (600 every two weeks for four cycles daily Pegfilgrastim (G-CSF) that administered 3–10 days after each...
Background and Objectives: Complete revascularization is not possible in up to 37% of patients with coronary artery disease (CAD). Therapeutic angiogenesis may be considered as an option the management these patients. The aim present study was evaluate effectiveness safety therapeutic using basic fibroblast growth factor CAD. Methods: In this double-blind, placebo-controlled study, eighteen a severe diffuse atherosclerotic along left anterior descending (LAD) who were CABG candidate at least...
Background/Aims. The anthracycline and taxane-based chemotherapy regimens are the standard adjuvant treatment of node-positive breast cancer patients. Although it was believed that docetaxel paclitaxel similarly effective as in cancer, recent studies report weekly is superior to triweekly schedules terms overall survival (OS) disease-free (DFS). However, best our knowledge, no study has compared with a dose-dense regimen docetaxel. current aimed at evaluating outcome women who had received...